Author pages are created from data sourced from our academic publisher partnerships and public sources.
Share This Author
T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial
Cancer Regression in Patients After Transfer of Genetically Engineered Lymphocytes
The ability to specifically confer tumor recognition by autologous lymphocytes from peripheral blood by using a retrovirus that encodes a T cell receptor is reported.
Cancer Regression and Autoimmunity in Patients After Clonal Repopulation with Antitumor Lymphocytes
The adoptive transfer of highly selected tumor-reactive T cells directed against overexpressed self-derived differentiation antigens after a nonmyeloablative conditioning regimen resulted in the persistent clonal repopulation of T cells in cancer patients, leading to regression of the patients' metastatic melanoma as well as to the onset of autoimmune melanocyte destruction.
Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2.
- R. Morgan, J. Yang, M. Kitano, M. Dudley, C. Laurencot, S. Rosenberg
- Biology, MedicineMolecular therapy : the journal of the American…
- 1 April 2010
It is speculated that the large number of administered cells localized to the lung immediately following infusion and were triggered to release cytokine by the recognition of low levels of ERBB2 on lung epithelial cells, consistent with a cytokine storm.
Cancer immunotherapy: moving beyond current vaccines
Results in cancer vaccine trials are considered and alternate strategies that mediate cancer regression in preclinical and clinical models are highlighted.
Adoptive cell transfer as personalized immunotherapy for human cancer
The ability to genetically engineer lymphocytes to express conventional T cell receptors or chimeric antigen receptors has further extended the successful application of ACT for cancer treatment.
A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer.
Bvacizumab can significantly prolong the time to progression of disease in patients with metastatic renal-cell cancer, and this trial was stopped after the interim analysis met the criteria for early stopping.
Adoptive cell transfer: a clinical path to effective cancer immunotherapy
- S. Rosenberg, N. Restifo, J. Yang, R. Morgan, M. Dudley
- Medicine, BiologyNature Reviews Cancer
- 1 April 2008
The ability to genetically engineer human lymphocytes and use them to mediate cancer regression in patients has opened possibilities for the extension of ACT immunotherapy to patients with a wide variety of cancer types and is a promising new approach to cancer treatment.
Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen.
T cells expressing highly reactive TCRs mediate cancer regression in humans and target rare cognate-antigen-containing cells throughout the body, a finding with important implications for the gene therapy of cancer.
A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone.
This immunotherapeutic approach can result in marked tumor regression in some patients for whom no other effective therapy is available at present, and determining its ultimate role in cancer therapy awaits further attempts to increase the therapeutic efficacy of treatment and decrease its toxicity and complexity.